⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Recursion Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Recursion Pharmaceuticals
↗Salt Lake City, Utah, USA
Recursion Pharmaceuticals is a clinical-stage TechBio company pioneering AI-driven drug discovery and development. Founded in 2013, the company uses proprietary machine learning platforms, high-throughput automation, and massive biological datasets (>50 petabytes) spanning phenomics, transcriptomics, proteomics, and ADME data to identify novel drug targets and develop potential first-in-class and best-in-class therapies. The company operates an advanced automated wet lab using robotics and computer vision to capture millions of cell experiments weekly, complemented by proprietary AI foundation models (Phenom family) and large language models. In November 2024, Recursion completed the acquisition of Exscientia, merging two AI-driven drug discovery leaders to create an integrated end-to-end platform combining Recursion's biology exploration capabilities with Exscientia's precision chemistry and automated synthesis.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals/Biotechnology
Sub-Industry:AI-driven drug discovery (TechBio)
SIZE & FINANCIALS
Employees:501-1000
Revenue:$58.8M (2024) to $39.4M (2025 YTD through Q3)
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$461M
Investors:Felicis Ventures, DCVC (Data Collective), Advantage Capital, Baillie Gifford, Mubadala, Lux Capital, Obvious Ventures, EPIC Ventures, Two Sigma Ventures, Intermountain Ventures, Nvidia, Leaps by Bayer
STOCK
Exchange:NASDAQ
Ticker:RXRX
Market Cap:$1.81B
PIPELINE
Stage:Phase 1-2
Lead Drug Stage:Phase 2 (REC-4881 showing clinical proof of concept)
Modalities:Small molecule, MEK Inhibitors, RBM39 Degraders, Novel targeted therapies
Active Trials:7
Trial Phases:Phase 1: 3 | Phase 2: 4
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Exscientia (acquired November 2024)
Key Partnerships:Roche & Genentech (neuroscience, oncology, gastroenterology oncology collaboration with $500M+ in upfront and milestone payments), Google Cloud (cloud infrastructure, generative AI exploration), NVIDIA (supercomputing infrastructure for BioHive-2), Merck (through co-founder Dean Li)
COMPETITION
Position:Leader
Competitors:Relay Therapeutics, Schrödinger, BenevolentAI, Insilico Medicine, Owkin, Valo Health, Turbine, BioMap
LEADERSHIP
Key Executives:
Najat Khan, Ph.D. - Chief Executive Officer and President (effective January 1, 2026)
Chris Gibson, Ph.D. - Chairman (transitioned from CEO January 1, 2026)
Rob Hershberg, MD/Ph.D. - Vice-Chairman and Lead Independent Director
Scientific Founders:Chris Gibson, Ph.D. - Co-founder, bioengineer, Dean Li, M.D., Ph.D. - Co-founder, now President of Merck Research Laboratories, Blake Borgeson, Ph.D. - Co-founder, bioinformatics specialist from Rice University and UT Austin
Board Members:Chris Gibson (Chair), Najat Khan, Rob Hershberg, Elaine Sun (COO/CFO at Mammoth Biosciences)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Recursion Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.